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The success of anti-smoking policies implemented 
in many developed countries has to a large extent 
been countered by the efforts of a highly resilient 
tobacco industry to target developing countries, 
many of which have less stringent anti-smoking 
strategies. Indeed, developing countries are now estimated to 
account for >70% of global tobacco consumption.[1,2] The increase 
in the frequency of smoking has coincided with the HIV/ AIDS 
pandemic in developing countries, presenting an ominous, 
interactive threat to public health. This is based on a number of 
studies, mainly from the USA and Europe, reporting that HIV-
infected persons have extremely high rates of cigarette smoking,[3,4] 
associated, in turn, with a higher than expected increase in the 
frequency of co-morbidities, including cardiovascular diseases, 
bacterial pneumonia and cancers, as well as increased mortality. [3-6] 
Despite unrestricted access to advanced care and therapy, HIV-
positive smokers appear to lose more life years from smoking 
than from HIV infection.[5] Moreover, smoking not only impacts 
negatively on the efficacy of antiretroviral therapy (ART),[7] but is 
also associated with treatment failure in tuberculosis (TB).[8]
Although the frequency of cigarette smoking in the general 
population in South Africa (SA), home to the largest number of 
HIV-positive people in the world, is estimated to be 16%,[9] the 
frequency in HIV-positive persons is uncertain. In a small pre-ART 
study conducted in a group (N=41) of predominantly male (n=34) 
subjects with pulmonary TB, the frequencies of cigarette smoking, 
measured according to urine cotinine concentrations, in the entire 
group, as well as in a subgroup of HIV-seropositive patients (n=10) 
were reported to be 63% and 70%, respectively, with cotinine 
concentrations rising significantly after 6 months of therapy.[10] These 
figures are comparable with a more recent study in a larger number of 
SA patients with active or latent TB in which the reported frequencies 
of cigarette smoking for the entire group (N=424) and the HIV-
positive subgroup (n=119) were 68% and 71%, respectively.[11]
Given the relative paucity of data on this priority public health 
issue,[12] the current study was undertaken to establish the frequency 
and demographics of cigarette smoking and other types of substance 
abuse among HIV-positive patients attending the HIV Clinic at 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), 
Johannesburg, SA.
Methods
This was a prospective cross-sectional survey of HIV-positive 
patients attending the HIV Clinic at CMJAH between 1 July and 31 
October 2011. The hospital is a tertiary academic institution, which 
has an HIV clinic providing ART. All patients who entered into the 
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Background. While the detrimental effects of smoking among HIV-positive patients have been well documented, there is a paucity of data 
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Objectives. To establish the frequency, demographics, knowledge of harmful effects, and knowledge of smoking cessation strategies among 
HIV-positive patients in Johannesburg, SA.
Methods. We conducted a prospective cross-sectional survey using a structured questionnaire to interview HIV-positive patients attending 
the HIV Clinic at the Charlotte Maxeke Johannesburg Academic Hospital between 1 July and 31 October 2011. 
Results. Of 207 HIV-positive patients attending an antiretroviral therapy (ART) roll-out clinic, 31 (15%) were current smokers (23.2% 
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wish to quit smoking, and among the group as a whole, most patients were aware of the general (82.1%) and HIV-related (77.8%) risks 
of smoking and of methods for quitting smoking. Despite this, however, most (62.3%) were not aware of who they could approach for 
assistance and advice. 
Conclusions. Given the relatively high prevalence of current and ex-smokers among HIV-positive patients, there is a need for the 
introduction of smoking-cessation strategies and assistance at ART roll-out clinics in SA. 
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study gave signed informed consent for participation. The study was 
approved by the Human Research Ethics Committee of the University 
of the Witwatersrand. 
All patients were interviewed using a structured questionnaire 
that recorded demographic and clinical details and a detailed 
history of smoking status. Patients were also questioned about their 
knowledge of the overall harmful effects of smoking, as well as the 
effects of smoking on HIV infection, their knowledge of smoking-
cessation strategies and previous attempts to quit. In 147 patients, 
a urine sample was tested for cotinine levels (ng/ml) using a solid-
phase competitive enzyme-linked immunosorbent assay (ELISA) 
(Calbiotech Inc., USA). A value >25  ng/ml was considered to be 
indicative of active smoking. 
Data were entered into data sheets. Basic frequency analyses were 
used to describe the mean values and ranges on continuous variables, 
whereas proportions were used in the case of non-continuous 
variables.
Results
A total of 207 patients were entered into the database, of whom 
108 (52.2%) were female. The majority (94.2%) of patients were 
black (white patients and coloured patients both 2.9%) reflecting 
the demographics of the clinic. The mean age of the patients was 
39.9 years (range 19 - 62). 
Overall, 31/207 (15%) were self-described current smokers, of 
whom 23/99 were male (23.2%) and 8/108 were female (7.4%). 
The average age of onset of smoking was 20 years (range 9 - 46). 
The average number of cigarettes smoked per day was 9 (range 
1 - 30  cigarettes/day). There were 45/207 (21.7%) patients who 
were ex-smokers and 131/207 (63.3%) who had never smoked. Two 
patients were current smokers of cannabis in addition to cigarettes. 
Six patients also currently used snuff. 
Most (30/31; 96.7%) smokers indicated that they wished to stop 
smoking for reasons shown in Table 1 (mainly expressing concern 
regarding health issues, but including HIV-positive diagnosis, 
concurrent illness, costs and also personal, family and religious 
concerns). A majority of the total patient population (170/207; 
82.1%) indicated that they knew about the potential harmful effects 
of cigarette smoking in general, although several participants could 
not name a specific health hazard (Table 2). The majority (161/207; 
77.8%) had knowledge of the potential harmful effects of cigarette 
smoking, specifically in relation to HIV infection; 34/207 (16.4%) 
believed there were no harmful effects of smoking on HIV infection 
and 12/207 (5.8%) were unsure. 
Quitting had been attempted by 64/76 (84.2%) current and 
ex-smokers. A majority (58%) indicated an awareness of methods 
for quitting smoking. Most patients (62.3%) were unaware of the 
resources available for advice and assistance. 
As shown in Table 3, 82 patients were unaware of smoking-
cessation agents/adjuncts, 66 patients indicated that various food 
substances and drinks were of value, 35 patients had knowledge 
of going ‘cold turkey’; 33 patients were unable to name quitting 
techniques and 33 had knowledge of psychotherapy, avoiding 
smokers and drinkers, keeping busy, exercise, religion and prayer, 
rehabilitation and hypnotherapy. Twenty patients described various 
forms of nicotine replacement therapy (patches, gum and sprays), 
11 patients described various drugs, such as bupropion, 9 patients 
described weaning from smoking and 9 patients described various 
forms of cigarettes (electronic, nicotine-containing or nicotine-free 
cigarettes). No data were recorded in 5 patients. 
Urine specimens were obtained from 141 patients (21 current 
smokers, 31 ex-smokers and 89 non-smokers, Table 4) permitting 
measurement of cotinine levels. Cotinine levels were raised (>25 ng/ ml) 
in 43/141 patients (30.5% – 21 non-smokers, 10 ex-smokers and 12 
current smokers). Nine patients who were smokers did not have raised 
cotinine levels. All female smokers had raised cotinine levels as did 6 of 
the male smokers (with an additional 9 male smokers who had cotinine 
levels that were not in the positive range).
Discussion
The main findings of this study of 207 HIV-infected patients attending 
an ART roll-out clinic were that 15% were current smokers and that 
the majority had indicated their wish to quit smoking. Furthermore, 
most were aware of the general (82.1%) and HIV-related (77.8%) risks 
Table 1. Reasons given by current and ex-smokers for 
wishing to quit (N=76)
Health concerns 37
Finances 8
HIV diagnosis 7
Personal reasons 7
Concurrent illness 6
Other 5
Not indicated 2
Family 2
Religion 2
Table 2. Health-related effects identified by patients indicating a 
knowledge of harmful effects of cigarette smoking (N=170)*
Cancer 52
Tuberculosis 41
Emphysema 37
Not able to name a harmful effect 32†
Bad body odour 24
Effects on HIV medication 3
* Sometimes multiple reasons given.† Not able to name a harmful effect even those who had indicated that they were aware of 
harmful effects.
Table 3. Knowledge of methods used as part of smoking-
cessation strategies (N=207)*
No techniques known 82
Use of food-related items† 66
Going ‘cold turkey’ 35
Unable to name a technique‡ 33
Other methods 33
Nicotine replacement therapy 20
Tablets/bupropion 11
Specialised cigarettes 9
Weaning 9
Data unknown 5 
* Sometimes multiple methods given. † Most commonly the use of sweets and chewing gum were indicated.‡ Unable to name a technique even, though they had indicated knowledge of different 
techniques.
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of smoking, and of methods for quitting 
smoking, but 62.3% were not aware of the 
resources available for assistance and advice. 
The overall prevalence of current smoking 
in the present study, based on the patient 
history, was 15%. This is similar to the 
frequency of smoking previously estimated 
in the general population in SA,[9] but much 
lower than that found in previous studies 
of HIV-infected SA people.[9-11] Factors that 
may have contributed include the fact that 
this study sampled a predominantly black 
SA population known to smoke less than 
any of the other population groups in the 
country, and there was a greater proportion 
of females (black females being much less 
likely to smoke).[9] 
The true frequency of smoking may have 
been underestimated, since it was based 
on patient history alone, whereas the urine 
cotinine levels were actually raised in 43/141 
patients (30.5%). The discrepancy was 28.4% 
(40/141 patients) between positive reported 
smoking history and elevated urine cotinine 
level (Table 4). In 19 males who indicated that 
they were either ex-smokers or non-smokers, 
the cotinine levels were raised (Table 4). The 
exact reasons for these discrepancies are 
uncertain, and while a discrepant history 
alone may be the major reason, it is possible 
that the relatively low numbers of cigarettes 
smoked or even intermittent smoking might 
offer an explanation. Passive exposure to 
cigarette smoke could have played a role, but 
possible passive smoking was not recorded. 
Interestingly, in 9 males who indicated 
they were current smokers the urine cotinine 
levels were not raised (Table 4). Cotinine 
is the major metabolite of nicotine. It has 
a comparatively long half-life of about 17 
hours in body fluid and is widely accepted as 
a sensitive and reliable marker of exposure to 
cigarette smoke and is considered to be more 
reliable than smoking history in determining 
smoking status.[11,12] One study[13] indicated a 
relatively poor correlation between patient 
history and the urine cotinine levels, 
especially in ex-smokers in whom smoking 
history can be misleading. 
Encouragingly, most of the study 
population had insight into the general 
health and HIV-associated risks of smoking 
and almost all the ever-smokers indicated 
their willingness to quit smoking. That most 
of the study population lacked knowledge 
of resources offering assistance and advice, 
suggests the possibility for a public health 
intervention.
Cigarette smoking impacts on mortality, 
quality of life and co-morbid illnesses in 
HIV-infected patients,[3] even subsequent to 
the introduction of highly active ART. [4] 
There are serious medical conditions 
associated with cigarette smoking, including 
cardiovascular disease, pulmonary diseases 
and cancers,[14] with further good evidence 
that these risks decrease on smoking 
cessation. Although the prevalence of 
smoking in the current study is substantially 
lower than that reported in developed 
countries, the overwhelming infectious 
disease burden in the developing world 
potentially compounds its adverse effects. 
It is incumbent on all healthcare workers 
to encourage their HIV-infected patients to 
quit smoking.[4,15] 
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Table 4. Association between smoking histories and cotinine levels
Cotinine levels (ng/ml)
<25 >25 - 50 >50 - 75 75 - 100 >100
Males, n
Smokers 9 0 1 0 5
Ex-smokers 18 1 2 0 6
Non-smokers 24 1 0 0 9
Females, n
Smokers 0 0 0 1 5
Ex-smokers 3 0 0 0 1
Non-smokers 44 4 1 0 6
